Synthesis and characterization of amoxicillin-loaded polymeric nanocapsules as a drug delivery system targeting Helicobacter pylori

Abdelghany, Aya; El-Desouky, Mohamed A.; Shemis, Mohamed

doi:10.1016/j.ajg.2021.06.002

Cited by 11 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, blank PCL nanocapsules have been studided in parallel and results showed that the empty vehicles were safe on normal Vero cells (97–100% viability) and had a negligible cytotoxic effect on HepG2 cells (93–100% viability). Which agrees with [ 69 , 70 ], approving that the blank PCL nanocapsules have almost no cytotoxic effect on the normal Vero cell line. Also, according to [ 71 ], the PCL showed in vitro antiproliferative and antioxidant effects against HepG2 cancer cells while causing opposite action on healthy hepatocytes by increasing their survival until 4 weeks in culture.…”

Section: Discussionsupporting

confidence: 90%

Synthesis, characterization, and cytotoxicity of doxorubicin-loaded polycaprolactone nanocapsules as controlled anti-hepatocellular carcinoma drug release system

et al. 2022

View full text Add to dashboard Cite

Background Free doxorubicin (Dox) is used as a chemotherapeutic agent against hepatocellular carcinoma (HCC), but it results in cardiotoxicty as a major side effect. Hence, a controlled Dox drug delivery system is extremely demanded. Methods Dox was loaded into the non-toxic biodegradable polycaprolactone (PCL) nanocapsules using the double emulsion method. Characterization of Dox-PCL nanocapsules was done using transmission electron microscopy and dynamic light scattering. Encapsulation efficiency and drug loading capacity were quantified using UV–visible spectrophotometry. Drug release was investigated in vitro at both normal (7.4) and cancer (4.8) pHs. Cytotoxicity of Dox-PCL nanocapsules against free Dox was evaluated using the MTT test on normal (Vero) and hepatic cancer (HepG2) cell lines. Results Spherical nanocapsules (212 ± 2 nm) were succeffully prepared with a zeta potential of (-22.3 ± 2 mv) and a polydisperse index of (0.019 ± 0.01) with a narrow size distribution pattern. The encapsulation efficiency was (73.15 ± 4%) with a drug loading capacity of (16.88 ± 2%). Importantlly, Dox-release from nanocapsules was faster at cancer pH (98%) than at physiological pH (26%). Moreover, although Dox-PCL nanocapsules were less toxic on the normal cell line (GI 50 = 17.99 ± 8.62 µg/ml) than free Dox (GI 50 = 16.53 ± 1.06 µg/ml), the encapsulated Dox showed higher toxic effect on cancer HepG2 cells compared to that caused by the free drug (GI 50 = 2.46 ± 0.49 and 4.22 ± 0.04 µg/ml, respectively). Conclusion The constructed Dox-PCL nanocapsules constitute a potentially controlled anti-HCC therapy with minimal systemic exposure. Graphical Abstract

show abstract

Section: Discussionsupporting

confidence: 90%

Synthesis, characterization, and cytotoxicity of doxorubicin-loaded polycaprolactone nanocapsules as controlled anti-hepatocellular carcinoma drug release system

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The incorporation of antimicrobial peptides appears as a promising alternative for infection treatment, as well as carvacrol loaded onto nanocapsules formed by PCL [55]. PCL nanocapsules loaded with amoxicillin trihydrate were prepared to investigate the gastric stability of this drug, as well as its therapeutic activity against H. pilori [56]. Eudragit ® polymers (polymethacrylate-based copolymers) are easy to handle and are used to prepare formulations for oral administration.…”

Section: Antimicrobial and Antibioticsmentioning

confidence: 99%

“…Antimicrobial and antibiotics Fluoxetine Polymeric [54] Carvacrol Polymeric [55] Amoxicillin Polymeric [56] Florfenicol Polymeric [57] Tea tree oil Polymeric [58] Fusidic acid Lipid [59] Albendazole Lipid [60] Anticancer drugs Curcumin Polymeric [61][62][63] Hybrid lipid [64] Liquid lipid [65,66] Docetaxel Polymeric [67,68] Lipid [69] Perillyl alcohol Polymeric [70] Tamoxifen Polymeric [71,72] Aprepitant Polymeric [73] 5-fluoroacil Polymeric [74,75] Doxorubicin Polymeric [76] Paclitaxel Polymeric [77,78] Lipid [79] Oleic acid Hybrid [80] Simvastatin Hybrid [81] Thymoquinone Polymeric [82] Gemcitabine Lipid [83] Phloretin Lipid [84] Itraconazole Lipid [85,86] Regorafenib Lipid [87] Sorafenib Lipid [88] Imatinib Lipid [89] Ifosfamide Lipid [90] Vinorelbine Lipid [91] Anti . Chitosan-PCL core-shell nanocapsules were obtained and loaded with tea tree oil.…”

Section: Pharmacological Group Drug/compound Type Of Nanocapsule Refe...mentioning

confidence: 99%

Lipid and Polymeric Nanocapsules

Rochín-Wong¹,

Rivas²

2022

Drug Carriers

View full text Add to dashboard Cite

In recent years, innovative drug nanocarriers have been developed to enhance stability, bioavailability, and provide sustained release. In this chapter, systems based on natural macromolecules, lipids, or polymeric/polyelectrolyte nanocapsules and their principal chemical and functional characteristics are described. Nano-vesicular systems are especially relevant in different fields. Particularly, a promising potential is offered by systems based on colloidal nanocapsules, that exhibit a typical core-shell structure in which the drug can be confined into the cavity or in the polymeric coating that surrounds it. Both the cavity and the active substance can be lipophilic or hydrophilic and in solid or liquid form depending on the materials and methods used, making these nanocapsules attractive carriers for drug delivery. In addition, a compilation of different methods and materials employed in the preparation of these nanosystems and a recent review of applications of lipid and polymeric nanocapsules have been made, focussing on the encapsulation of drugs.

show abstract

“…Another approach is the preparation of nanostructured formulations such as polymeric nanoparticles [ 112 ] and liposomes [ 106 ] containing AMOX. The design of mucoadhesive liposomes has been conducted with success by the preparation of pectin-coated liposomes.…”

Section: Solution Ii: Development Of Smart Gastroretentive Ddssmentioning

confidence: 99%

Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations

Grosso

de-Paz

2022

Pharmaceutics

View full text Add to dashboard Cite

Even though general improvement of quality of life has happened around the globe, statistics show that gastric cancer is still a very serious medical concern in some regions of the world. A big portion of malignant neoplasms that develop inside the stomach are linked to an infection of Helicobacter pylori; in fact, this pathogen has already been categorized as a group 1 carcinogen by the World Health Organization (WHO). Still, the efficacy of current anti-H. pylori therapeutic approaches is insufficient and follows a worrying decreasing trend, mainly due to an exponential increase in resistance to key antibiotics. This work analyzes the clinical and biological characteristics of this pathogen, especially its link to gastric cancer, and provides a comprehensive review of current formulation trends for H. pylori eradication. Research effort has focused both on the discovery of new combinations of chemicals that function as optimized antibiotic regimens, and on the preparation of gastroretentive drug delivery systems (GRDDSs) to improve overall pharmacokinetics. Regarding the last topic, this review aims to summarize the latest trend in amoxicillin-loaded GRDDS, since this is the antibiotic that has shown the least bacterial resistance worldwide. It is expected that the current work could provide some insight into the importance of innovative options to combat this microorganism. Therefore, this review can inspire new research strategies in the development of efficient formulations for the treatment of this infection and the consequent prevention of gastric cancer.

show abstract

Synthesis and characterization of amoxicillin-loaded polymeric nanocapsules as a drug delivery system targeting Helicobacter pylori

Cited by 11 publications

References 32 publications

Synthesis, characterization, and cytotoxicity of doxorubicin-loaded polycaprolactone nanocapsules as controlled anti-hepatocellular carcinoma drug release system

Synthesis, characterization, and cytotoxicity of doxorubicin-loaded polycaprolactone nanocapsules as controlled anti-hepatocellular carcinoma drug release system

Lipid and Polymeric Nanocapsules

Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations

Contact Info

Product

Resources

About